Autobio Diagnostics's achieved a net profit of 899 million CNY in the first three quarters

As a leading enterprise in China's in vitro diagnostic industry, Autobio Diagnostics CO.,Ltd. has continued to maintain a steady growth trend.

On October 25, Autobio Diagnostics 's third quarterly report was officially announced. In the first three quarters of this year, Antu Bio's revenue and net profit both maintained a year-on-year growth rate of over 20%. At the same time, with the initial prototype of Antu Bio's traditional chemiluminescence and molecular products dual-nuclear drive model, its future growth space is also further opened.

Financial data shows that in the first three quarters of 2022, Autobio Diagnostics achieved an operating income of 3.281 billion CNY, a year-on-year increase of 21.75%, a net profit of 899 million CNY attributable to the parent, a year-on-year increase of 25.44%, and a net profit of 860 million CNY after deducting non-returning to the parent. A year-on-year increase of 21.10%.

From a quarterly perspective, in the third quarter of 2022, the company achieved operating income of 1.211 billion CNY, a year-on-year increase of 19.02%, net profit attributable to the parent of 365 million CNY, a year-on-year increase of 20.23%, and deducted non-net profit of 355 million CNY, a year-on-year increase of 15.47%.

With the continuous growth of Autobio Diagnostics 's regular business, the cost dilution effect has become more and more significant, which has led to an increase in the company's profit margin. From the perspective of financial data, in the first three quarters of this year, Autobio Diagnostics 's sales expense ratio, management expense ratio, and financial expense ratio have declined to varying degrees. At the same time, the company's gross profit margin and net profit margin have slightly increased.

In addition, in the first three quarters of this year, Autobio Diagnostics still maintained a large amount of R&D investment. Financial data shows that in the first three quarters of this year, Antu Bio's R&D expenses were 397 million CNY, a year-on-year increase of 17.50%.

On September 26, Autobio Diagnostics released the "Announcement of the Company and its Subsidiaries Obtaining the Medical Device Registration Certificate". The announcement shows that Autobio Diagnostics and its subsidiaries have received 9 medical device registration certificates issued by the State Drug Administration and the Henan Provincial Drug Administration respectively.

In this regard, Autobio Diagnostics said that the acquisition of the above-mentioned medical device registration certificate has further enriched the company's product menu, continuously met market demand, is an effective supplement to the company's existing testing products, and can gradually improve the overall competitiveness of the company's products.